This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Accolade 향후 성장
Future 기준 점검 1/6
Accolade은 연간 수입과 매출이 각각 36%와 11.3% 증가할 것으로 예상되고 EPS는 연간 42.7%만큼 증가할 것으로 예상됩니다.
핵심 정보
36.0%
이익 성장률
42.74%
EPS 성장률
| Healthcare 이익 성장 | 18.4% |
| 매출 성장률 | 11.3% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 08 Apr 2025 |
최근 향후 성장 업데이트
Recent updates
새로운 내러티브 • Mar 27
Expanding Health Plan Partnerships Will Unlock Integrated Healthcare Solutions
Accolade’s partnership expansions and bundled solutions strategy aim to enhance revenue growth and elevate net margins.Seeking Alpha • Dec 05
Accolade: A GARP Stock Trading Well Under 1X Revenues
Summary Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overreaction to a minor revenue guidance decline. Its stock trades at a significant discount to its peers despite growing faster than all but one. I recommend a long position with a one-year price target of $7.00, driven by growth catalysts. Read the full article on Seeking AlphaSeeking Alpha • Sep 09
Accolade: Consider Both Short-Term Revenue Outlook And Rumored Takeover
Summary ACCD's revenue growth is projected to decelerate in FY 2025; the company's top line outlook for the new fiscal year remains weak, considering the latest staff redundancy numbers and the company's recent comments on costs. There are rumors suggesting that Accolade is putting itself up for sale, and ACCD's undemanding valuations suggest that the stock will be an attractive takeover candidate. I stick to my existing Hold rating for Accolade following an assessment of the company's near-term revenue growth prospects and the chances of a potential takeover. Read the full article on Seeking Alpha분석 기사 • Jun 29
Slammed 50% Accolade, Inc. (NASDAQ:ACCD) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Accolade, Inc. ( NASDAQ:ACCD ) shares are down a considerable 50% in the last...Seeking Alpha • Jun 28
Accolade: Mixed Guidance (Rating Downgrade)
Summary Accolade's full-year guidance was mixed, notwithstanding a Q1 FY 2025 results beat driven by a favorable timing factor. ACCD sees its revenue growth slowing from +14% last year to +13% in the current fiscal year, but its 3.7% FY 2025 EBITDA margin guidance was above expectations. My rating for Accolade is downgraded from a Buy to a Hold, after considering the company's outlook in light of its updated guidance. Read the full article on Seeking Alpha분석 기사 • Jun 05
Does Accolade (NASDAQ:ACCD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Apr 05
Accolade: Staying Bullish On Favorable Developments
Summary I like Accolade's choice of new partners added year-to-date, as I think the services provided by these partners will be well received by its clients' employees. ACCD's latest "Artificial Intelligence Excellence Award" presented by the Business Intelligence Group provides a validation of the potential AI-related tailwinds for the company. A review of Accolade's most recent developments leaves me bullish on the stock. Read the full article on Seeking Alpha분석 기사 • Feb 17
Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Seeking Alpha • Jan 17
Accolade: Remain Confident That FY25 Guided Growth Is Achievable
Summary I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion. Read the full article on Seeking AlphaSeeking Alpha • Jan 11
Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)
Summary ACCD's Q3 FY 2024 top line and non-GAAP adjusted EBITDA loss came in better than the Wall Street analysts had anticipated. Accolade also revised its FY 2024 revenue outlook upwards, and shared its updated expectations of a narrower EBITDA loss for the current fiscal year. I raise my rating for ACCD to a Buy, in consideration of the company's beat-and-raise quarter, its long-term prospects, and the stock's current valuations. Read the full article on Seeking Alpha분석 기사 • Jun 13
Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge
Accolade, Inc. ( NASDAQ:ACCD ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...분석 기사 • May 02
Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?
Accolade, Inc. ( NASDAQ:ACCD ), might not be a large cap stock, but it led the NASDAQGS gainers with a relatively large...분석 기사 • Feb 05
An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued
Today we will run through one way of estimating the intrinsic value of Accolade, Inc. ( NASDAQ:ACCD ) by taking the...Seeking Alpha • Oct 17
Accolade: Inching Closer To Profitability
Summary Accolade outperformed in Q2 2023 on another strong quarter of double-digit revenue growth. Full-year guidance has moved slightly higher, but there remains ample room for more upward revisions. With the fundamentals firmly intact despite the ongoing macro challenges, the current valuation seems undemanding. Personalized health and benefits solution platform Accolade's (ACCD) earnings momentum continued on the back of another solid Q2 2023, underpinning a positive outlook into the selling season ahead. With revenue growth in the double digits % as well, the upbeat guidance commentary for annual recurring revenue to exceed last year came as no surprise. The key to near-term upside will be execution - in particular, management's progress in clearing customers/RFPs outstanding (predominantly greenfield opportunities) will be worth keeping an eye on. In addition, FY24 could also benefit from timing issues related to when certain benefits go into effect (recall this was the rationale behind the upper end of this fiscal year's guidance remaining unchanged). As for the mid to long-term, the broad-based strength across the different product lines bodes well for the company's outlook, as customers increasingly recognize the value of ACCD's full suite of solutions. Net, ACCD looks well-positioned to weather the headwinds, delivering wins through a tough macroeconomic and competitive environment. Assuming ACCD makes good on its profitability targets (full-year adj EBITDA positive in FY25), the stock should quite easily grow into its undemanding 1-2x EV/Revenue valuation. Data by YCharts A Strong Q2 2023 Earnings Performance ACCD saw another strong quarter of growth, led by revenues of $87.6m (+19.6% YoY) and a gross margin expansion of ~380bps. Its adj EBITDA loss also narrowed to -$13.7m (excluding ~$3m in non-recurring severance expenses) - a significant improvement from -$19.4m in Q2 2022. This led to a similarly improved net loss for the quarter at -$46.5m (vs. $62.4m in the prior year). The cash buffer remains strong as well at $330.6m (down slightly from the $335.6m in the previous quarter and $384m last year). Against an ending debt balance of $281.5m (flat QoQ and modestly higher YoY), ACCD's net cash position remains intact. Accolade Driving the earnings outperformance was a combination of solid revenue growth and cost discipline across key segments and cost line items. This reflects not only the growing momentum in all of the business units, but also that recent acquisitions like ExpertMD and PlushCare have progressed well on their post-acquisition integration timelines. Importantly, management also indicated on the call that customers are recognizing the value-add of its total solution (including virtual primary care and second opinion services) in generating cost savings and an improved ROI for clients. The ACCD offering will be targeted at small to medium-sized businesses (<1k employees) looking for incremental cost savings and better staff retention. Updated FY23 Guidance Highlights Progress Toward Mid-Term Targets For Q3 2023, ACCD is guiding for revenues to be within the $86-88m range and for an adj EBITDA loss range of $11-13m, representing a ~14% EBITDA loss margin at the midpoint. While this is still a net upgrade from the prior guidance numbers, the extent of the raise (the upper end of next quarter's revenue guidance is intact) was a tad surprising. Given there was a ~$1.5m pull-forward of some revenue contribution to Q2, though, this was largely a timing issue rather than a signal of near-term weakness. In particular, some of the wins for ExpertMD/Care, which will start off-cycle, are contributing. More importantly, management commentary on the call suggests a strong selling season remains intact, potentially driving upside to these numbers. On a full-year basis, the revenue guidance was raised to a $358-365m range (above the $355-365m prior), although the EBITDA guidance was unchanged at a loss of $35-$40m, representing a ~10% EBITDA loss margin at the midpoint. The latter was a surprise, given another strong quarter of growth, positive commentary on the upcoming selling season, as well as positive EBITDA trends. Most likely, management is incorporating some buffer here in case of a significant macro downturn in the coming months, potentially leaving room for upward revisions ahead. That said, the long view is important, as the company continues to make good progress on its path to achieving EBITDA-level profitability by FY25. Accolade Underlying Fundamentals Point to Brighter Long-Term Prospects Testament to its underlying strength, ACCD has noted that demand this year is up YoY despite the current macro headwinds. While there could be some deceleration in the near term, the employment environment, where employers are looking to balance employee retention with lower costs and higher engagement, is supporting the company's growth. Of note, the shape of revenue for FY24 is guided to be similar to FY23, although there could be some upside here, given the company disclosed some wins would only flow through in later periods.Seeking Alpha • Oct 05
Accolade Q2 2023 Earnings Preview
Accolade (NASDAQ:ACCD) is scheduled to announce Q2 earnings results on Thursday, October 6th, after market close. The consensus EPS Estimate is -$0.50 (+48.5% Y/Y) and the consensus Revenue Estimate is $82.86M (+13.1% Y/Y). Over the last 1 year, ACCD has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 5 downward. Revenue estimates have seen 1 upward revision and 2 downward.Seeking Alpha • Aug 09
Accolade: Fair And Reasonably Priced, But Needs More Time
Accolade, Inc. came in with another strong quarter for its first of FY23, growing revenue 44% YoY. Investors have shied away from rewarding top-line growth this year however, and are focused on bottom-line fundamentals instead. In that vein, we notice ACCD displays a loose affinity to the kind of equity premia we are seeking exposure to. The stock appears fairly priced, and we rate ACCD neutral. Investment summary We are in search of selective opportunities within healthcare as we seek to move up the quality spectrum. Within the healthcare universe, there are numerous companies that exhibit the quality like premia investors are rewarding in FY22, whereas the sector traditionally performs well as a defensive in times of economic downturn. Nevertheless, quality - and in particular, profitability (ROE, ROIC, margins, etc.) - are paramount within the current regime. Here we turn to Accolade, Inc. (ACCD) and notice it displays a loose fit to these kind of factors. Whilst the company is churning away nicely towards its goals, it becomes a question of opportunity cost in the current landscape. Investors aren't rewarding just top-line growth in FY22, but bottom-line fundamentals instead. With these in mind, we rate ACCD neutral with a price target of $11.60-$11.80. Exhibit 1. ACCD 6-month price action Data: Updata Q1 FY23 earnings provide useful insights First quarter earnings for the company's new fiscal year came in with a strong beat at the top of $85.5 million, a 44% YoY growth schedule (although Q1 FY22 didn't include income from the PlushCare acquisition). ACCD recorded non-GAAP gross margin at 45.6%, up 560bps YoY, as seen in Exhibit 2. The decompression came from greater revenue contribution from the higher margin virtual primary care segment. We choose to refrain from adding back in stock-based compensation as it is realistically an expense in our estimation. Therefore, we estimate ACCD's non-GAAP gross margin (ex-stock-based compensation) to be 44.3%. Exhibit 2. ACCD reconciliation of GAAP to non-GAAP income Data: ACCD 10-Q, Q1 FY23 Moving down the P&L, non-GAAP EBITDA came in at a $15 million loss, worse than the loss of $12.8 million the year prior. The result came in ahead of guidance thanks to a lower operating spend and the impact from other non-cash charges. Following the three acquisitions of FY22, ACCD has grown headcount by 71% to ~2,400. As such, it was a 71% growth in headcount vs. a 44% and each employee generates $35.6K in quarterly revenue, based on Q1 FY23 results. Management says that it completed a strategic review of the business last quarter, and ended up narrowing the headcount down by ~4% as a result. Management also says it is still on track to be cash flow positive within the next 2-3 years. Alas, with the recent acquisitions, we need to see some further upside at the NOPAT level to substantiate this goal. As seen in Exhibit 3, ROIC has remained in the red despite the company's level of invested capital expanding QoQ since listing. Generating a ROIC that beats the company's WACC of 7.7% is integral to flourish in the current macro-regime, as the cost of capital is surging in both equity and debt capital markets. At present, ACCD isn't there yet, and we advocate this is a key litmus test for investors to focus on into the coming quarters to gauge if it is on track to be cash flow positive in 2-3 years as management hope. Exhibit 3. Return on investment has yet to pull through although trends are improving We look to ACCD's ROI as a key indicator on whether it is on track to hit cash flow positive in 2-3 years' time. Data: HB Insights, ACCD SEC Filings As a result, management upgraded FY23 guidance and forecasts a 16% YoY growth at the top, calling for $360 million in revenue at the midpoint of range. It also projects FY23 EBITDA to fall between $35-$40 million for the year. Management also foresees Q2 FY23 sales of $82-$83 million and non-GAAP EBITA loss of ~$20 million. It also reiterated its objective of achieving positive cash flow by FY25 (or around 2-3 years from now). Valuation somewhat supportive We note the ACCD share price has caught a bid since May and has curled back up to 3-month highs. It has also gained in relative strength versus the healthcare and healthcare providers sector, as seen in Exhibit 4. However, we also note this is likely to be a function of sector beta versus pure idiosyncratic reasons. Exhibit 4. ACCD has caught a bid since May however this looks to be sector beta versus company-specific drivers, as seen on the chart below. This is important - we're after selective opportunities within the healthcare space we move up into the quality matrix. In that vein, we need evidence of idiosyncratic (company-specific) risk drivers, and would ideally see sector beta reduce with improving relative strength. Data: Updata Shares are also fairly priced at 0.98x book and this trades at a deep discount to those in the peer group. Note, there are many long-standing, mature names in the list and therefore on an equity value the discount may be warranted. Shares are also priced at ~2.7x forward sales, implying that investors expect an above-market revenue growth next year for the company. Exhibit 5. Multiples and Comps (GICS Industry Sector) Data: HB Insights Shares also trade at a discount of 0.7x to tangible book relative to both market cap and enterprise value ("EV"). With this in mind, we'd theoretically be paying roughly fair price for ACCD at $11.60-$11.80, suggesting the stock is fairly priced trading at ~0.7x EV/Tangible book value.Seeking Alpha • Jun 29
Accolade Q1 2023 Earnings Preview
Accolade (NASDAQ:ACCD) is scheduled to announce Q1 earnings results on Thursday, June 30th, after market close. The consensus EPS Estimate is -$0.43 and the consensus Revenue Estimate is $81.97M (+37.8% Y/Y). Over the last 1 year, ACCD has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 1 upward revision and 8 downward.Seeking Alpha • Mar 28
Accolade: Little Recent Applause
Today, we put healthcare cloud concern Accolade in the spotlight for the first time. Despite solid growth and the addition of new capabilities since the company went public in July 2020, the stock finds itself in 'Busted IPO' territory. Brighter prospects for shareholders on the horizon? A full investment analysis follows in the paragraphs below.Seeking Alpha • Dec 16
Accolade Impresses With Revenue Growth But Faces Operating Losses
Accolade went public in July 2020, raising $220 million in a U.S. IPO. The firm provides a healthcare information platform for enterprises and end users. ACCD has grown topline revenue sharply but is producing high and increasing operating losses, so my outlook is Neutral on the stock.Seeking Alpha • Oct 18
Accolade: I May Add To My Position
Accolade has seen continued growth this year. Solid organic growth has been accelerated by two bolt-on deals announced this year. I like the accelerated growth trajectory as the bottom line performance has been lagging a bit, but nonetheless I see appeal increasing again.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 2/29/2028 | 628 | -74 | N/A | N/A | 2 |
| 2/28/2027 | 592 | -64 | N/A | N/A | 5 |
| 2/28/2026 | 524 | -68 | N/A | N/A | 8 |
| 2/28/2025 | 464 | -124 | N/A | N/A | 5 |
| 11/30/2024 | 447 | -180 | -13 | -7 | N/A |
| 8/31/2024 | 441 | -80 | -1 | 8 | N/A |
| 5/31/2024 | 432 | -89 | -15 | -4 | N/A |
| 2/29/2024 | 414 | -100 | -29 | -16 | N/A |
| 11/30/2023 | 388 | -123 | -37 | -25 | N/A |
| 8/31/2023 | 380 | -142 | -46 | -35 | N/A |
| 5/31/2023 | 371 | -155 | -39 | -30 | N/A |
| 2/28/2023 | 363 | -460 | -48 | -41 | N/A |
| 11/30/2022 | 358 | -464 | -46 | -40 | N/A |
| 8/31/2022 | 350 | -401 | -62 | -57 | N/A |
| 5/31/2022 | 336 | -417 | -69 | -65 | N/A |
| 2/28/2022 | 310 | -123 | -66 | -62 | N/A |
| 11/30/2021 | 275 | -93 | -53 | -50 | N/A |
| 8/31/2021 | 230 | -132 | -43 | -41 | N/A |
| 5/31/2021 | 194 | -85 | -47 | -45 | N/A |
| 2/28/2021 | 170 | -51 | -28 | -25 | N/A |
| 11/30/2020 | 156 | -48 | -49 | -46 | N/A |
| 8/31/2020 | 147 | -50 | -41 | -37 | N/A |
| 5/31/2020 | 140 | -49 | -29 | -26 | N/A |
| 2/29/2020 | 133 | -51 | -38 | -34 | N/A |
| 11/30/2019 | 123 | -56 | -25 | -23 | N/A |
| 2/28/2019 | 95 | -56 | -20 | -17 | N/A |
| 2/28/2018 | 77 | -61 | N/A | -38 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: ACCD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: ACCD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: ACCD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: ACCD 의 수익(연간 11.3%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: ACCD 의 수익(연간 11.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: ACCD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/04/09 18:40 |
| 종가 | 2025/04/07 00:00 |
| 수익 | 2024/11/30 |
| 연간 수익 | 2024/02/29 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Accolade, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Gillmor | Baird |
| Zhilin Long | Berenberg |
| Cynthia Avella Motz | Goldman Sachs |